Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia by Preiss, D, Rosenson, R, Jacobsen, T, Djedjos, C, Dent, R, Bridges, I, Miller, M

Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies by Sattar, N, Valensi, P, Preiss, D, Dent, R, Bridges, I, Ruzza, A, Cyrille, M, Handelsman, Y